Drug Profile
Research programme: tau protein targeting therapeutics - Cantabio Pharmaceuticals/University of Cambridge
Alternative Names: Chaperone-based therapeutics - Cantabio Pharmaceuticals/University of Cambridge; Tau protein modulators - Cantabio Pharmaceuticals/University of CambridgeLatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Elan Pharmaceuticals; Max Planck Research Unit for Structural Molecular Biology; NovALiX; University of Cambridge
- Developer Cantabio Pharmaceuticals; Elan Pharmaceuticals; Max Planck Research Unit for Structural Molecular Biology; NovALiX; University of Cambridge
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Tau protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Dementia
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in United Kingdom
- 28 Oct 2020 No recent reports of development identified for preclinical development in Dementia in United Kingdom
- 07 Sep 2016 Tau protein targeting therapeutics licensed to Cantabio Pharmaceuticals worldwide for the treatment of Alzheimer's disease and Demntia